Targeted therapies in adult soft tissue sarcomas.
Yang
Jia-Lin
JL
Crowe
Philip J
PJ
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000068258:Bevacizumab; D003131:Combined Modality Therapy; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D011034:Podophyllotoxin / Q000627:therapeutic use; D017526:Receptor, IGF Type 1 / Q000037:antagonists & inhibitors; D012509:Sarcoma / Q000378:metabolism / Q000628:therapy*; D012983:Soft Tissue Neoplasms / Q000378:metabolism / Q000628:therapy*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D066246:ErbB Receptors; D017526:Receptor, IGF Type 1; D011034:Podophyllotoxin